Aquestive Therapeutics Inc(AQST) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 9 at 6:47 PM ET (Korea 11/10 08:47)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.64 | Insider Own | 12.46% | Shs Outstand | 125.7M | Perf Week | -6.1% |
| Market Cap | 0.44B | Forward P/E | - | EPS next Y | -4.03% | Insider Trans | -1.06% | Shs Float | 110.0M | Perf Month | -25.94% |
| Enterprise Value | 0.50B | PEG | - | EPS next Q | -0.11 | Inst Own | 47.25% | Short Float | 25.08% | Perf Quarter | -19.73% |
| Income | -0.08B | P/S | 9.11 | EPS this Y | 39.89% | Inst Trans | -1.33% | Short Ratio | 9.83 | Perf Half Y | -18.43% |
| Sales | 0.05B | P/B | - | EPS next 5Y | 22.72% | ROA | -56.05% | Short Interest | 27.60M | Perf YTD | -45.2% |
| Book/sh | -0.56 | P/C | 4.92 | EPS past 3/5Y | 11.13% 13.92% | ROE | - | 52W High | -47.44% ($6.74) | Perf Year | -41.39% |
| Cash/sh | 0.72 | P/FCF | - | Sales past 3/5Y | -2.24% -0.58% | ROIC | -102.71% | 52W Low | 20.82% ($2.93) | Perf 3Y | 107.02% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 8.82% | Gross Margin | 65.34% | Volatility(W/M) | 7.37% 6.17% | Perf 5Y | -43.18% |
| Dividend TTM | - | EV/Sales | 10.33 | Sales Y/Y TTM | 12.54% | Oper. Margin | -114.12% | ATR (14) | 0.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.69 | EPS Q/Q | 5.94% | Profit Margin | -162.33% | RSI (14) | 31.69 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.12 | Sales Q/Q | -40.99% | SMA20 | -11.13% ($3.98) | Beta | 1.52 | Target Price | $9.33 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/3 | SMA50 | -21.38% ($4.5) | Rel Volume | 1.51 | Prev Close | $3.61 |
| Employees | 147 | LT Debt/Eq | - | EPS/Sales Surpr. | -8.33% -31.41% | SMA200 | -16.11% ($4.22) | Avg Volume(3M) | 2.81M | Price | $3.54 |
| IPO | 2018/7/25 | Option/Short | Yes/Yes | Trades | 10682 | Volume | 4,237,315 | Change | -1.94% |
💊 Aquestive Therapeutics is a pharmaceutical company that develops and commercializes treatments for central nervous system disorders and allergic reactions based on its proprietary PharmFilm oral-soluble film technology. Founded in 2004 and headquartered in the United States, the company pursues a differentiated approach to needle-free drug delivery, including a film-based drug portfolio for seizures, epilepsy, and addiction, as well as a sublingual epinephrine film for anaphylaxis. Its US Nasdaq-listed ticker is AQST.
Over the past 1 year, on the lower side
47% below its 1-year high.
Traded more than usual. That is 151% of its average volume.
AQST has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.9% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $911. Peers typically go for $181.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -43.2%. The S&P 500 did +61% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
25.1% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #40 of 83 in the industry
Based on market cap of $445M.
TKNO#38 Alpha Teknova Inc $538M PER - 
EOLS#39 Evolus Inc $462M PER - AQST#40 Aquestive Therapeutics Inc $445M PER - 
KMDA#41 Kamada Ltd $444M PER 20.2 
TLRY#42 Tilray Brands Inc $421M PER - 
FAQ
What kind of company is AQST?
AQST belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AQST?
The market cap of AQST is approximately $445M, ranking 3,243 within its sector.
What is the 52-week high and low for AQST?
AQST has recorded a 52-week high of $6.74 and a low of $2.93.
